FDA grants full approval to new Alzheimer's drug meant to slow disease
FDA grants full approval to new Alzheimer's drug meant to slow disease
www.nbcnews.com FDA grants full approval to new Alzheimer's drug meant to slow disease
Approval will expand access to the drug, which will be covered by Medicare under certain circumstances.
1
comments
Leqembi, from Japanese drugmaker Eisai and U.S.-based drugmaker Biogen, targets a type of protein in the brain called beta-amyloid, long thought by scientists to be one of the underlying causes of Alzheimer’s disease.